SecBot SecBot

SNSE

Sensei Biotherapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001829802 Biotech & Drug Discovery
Former ticker of Sensei Biotherapeutics, Inc. · FTH stock page →
—
Median target
$50.00
range $50.00–55.00
Short interest
615.4K
−22.9%
Days to cover
9.1
at average volume
Insider net
−$750.2K
1 buyer · 3 sellers · since Mar 27
Filing reports
15
analyzed by SecBot
SecBot read BEARISH 5 reports · latest
Balance 2 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BEARISH Sensei Biotherapeutics (SNSE) filed an 8-K confirming its name change to Faeth Therapeutics (ticker FTH…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $889.6K at an average $29.35. 3 insiders sold $1.6M.

  • Short sellersCOVERING

    Short interest −22.9% to 615.4K shares. 9.1 days to cover.

The Street

last action Jun 2026
Recent actions
DateFirmActionRating
Jun 22, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Jun 15, 2026BTIG
REITERATE
REITERATEBuy
Jun 11, 2026BTIG
INITIATE
INITIATEBuy
May 29, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
May 28, 2026LUCID CAPITAL MARKETS
INITIATE
INITIATEBuy
May 22, 2026Citigroup
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 2, 2026
Clinical Trial
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 2 · COMPLETED
May 4, 2026
Earnings date
SNSE Q1 2026 Earnings Scheduled — 2026-05-04
Mar 26, 2026
Earnings date
SNSE Q4 2025 Earnings After Market Close — 2026-03-26
Mar 16, 2026
Short interest
FTD: SNSE — 26,041 shares ($0.8M) failed to deliver
Settlement: 20260316, Price: $32.28, FTD Value: $840,603.48, SENSEI BIOTHERAPEUTICS INC COM
Mar 11, 2026
Short interest
FTD: SNSE — 17,191 shares ($0.5M) failed to deliver
Settlement: 20260311, Price: $30.00, FTD Value: $515,730, SENSEI BIOTHERAPEUTICS INC COM

Insider ledger

Form 4
$889.6K
bought · 1 insider
$1.6M
sold · 3 insiders
DateInsiderTypeValue
Jun 10, 2026
Holmen Bob
Director
AWARD12,500 sh
Jun 10, 2026
Donenberg Phillip B.
Director
AWARD12,500 sh
Jun 10, 2026
Gerry Christopher
President & PEO
AWARD220,000 sh
Jun 1, 2026
Peyer James
10%+ Owner
SELL$490.5K
Jun 1, 2026
Cambrian BioPharma Inc
10%+ Owner
SELL$490.5K
Jun 1, 2026
Cambrian BioPharma Inc
10%+ Owner
SELL$10.1K
Jun 1, 2026
Peyer James
10%+ Owner
SELL$10.1K
Apr 10, 2026
Donenberg Phillip B.
Director
AWARD23,100 sh

Earnings setup

Estimates
−$6.42
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Next Q-$6.98-$10.44–-$1.00-869.9%$0.00
Current FY-$132.38-$161.01–-$101.68-4679.2%$0.00
Current Q-$6.42-$10.07–-$0.98-857.7%$0.00
Next FY-$9.21-$13.86–-$4.13-144.3%$0.00

Short side

FINRA· Jun 15, 2026
615,413
shares short
-22.9%
vs prior settlement
9.1
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 16, 2026 SEC
Saira Ramasastry filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing option grants…
3 — Impact 3/10
Jun 15, 2026 SEC
Sensei Biotherapeutics (SNSE) filed an 8-K confirming its name change to Faeth Therapeutics (ticker FTH effective June…
8-K — Impact 6/10
Jun 15, 2026 SEC
The SEC declared effective Sensei Biotherapeutics' S-3 shelf registration on June 12, 2026, registering up to…
EFFECT — Impact 6/10
Jun 10, 2026 Insider
Holmen Bob was granted 12,500 shares
Director
Jun 10, 2026 Insider
Donenberg Phillip B. was granted 12,500 shares
Director
Jun 10, 2026 Insider
Gerry Christopher was granted 220,000 shares
President & PEO
May 4, 2026 Earnings calendar
SNSE Q1 2026 Earnings Scheduled — 2026-05-04

SecBot reports

15 filings · 0 bullish · 6 bearish · 9 neutral
All SNSE filing & press-release reports (15)